Skip to main content

CAR-T Therapies Get $1 Billion Boost

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

Modifying T cells to express chimeric antigen receptors (CARs) that recognize cancer-specific antigens is a hot area of cancer immunotherapy. © LUCY READING-IKKANDACancer therapies that use modified T cells that express chimeric antigen receptors (CARs) as a way to target and kill tumor cells just got a big shot in the arm. Celgene, the global biopharmaceutical company headquartered in New Jersey, signed a $1 billion deal with Juno Therapeutics to develop CAR T-Cell immunotherapies for cancer.

“This transaction strengthens Celgene’s position in the emerging and transformative area of immuno-oncology,” Bob Hugin, chairman and CEO of Celgene, said in a statement from the company. “Juno has assembled world class experts and built impressive capabilities and technologies in the areas of T-cell biology and cellular therapy; we believe this long-term collaboration enhances the potential of both companies to deliver transformational therapies to patients with significant unmet medical needs.”

The specifics of the deal are still taking shape, but so far, investors know that Celgene will have options to commercialize Juno’s programs outside North America, while Juno will retain the rights to do so inside North America. Celgene is essentially buying about 9.1 million shares—roughly 10 percent—of Juno stock to complete the deal. This ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Related Topics

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Logo

Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven  Discovery

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Illustrated floating metabolites and molecules

Metabolon Verus™ Kit: Metabolomics Profiling Kit

Metabolon
Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler